An Open-Label Extension Study of APD811-003 in Patients With Pulmonary Arterial Hypertension

Trial Profile

An Open-Label Extension Study of APD811-003 in Patients With Pulmonary Arterial Hypertension

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Ralinepag (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Sponsors Arena Pharmaceuticals
  • Most Recent Events

    • 04 Feb 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.
    • 10 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 04 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top